Company profile: Advitos

1.1 - Company Overview

Advitos

Headquarter: Germany

Founded: 20XX🔒

Employees: 100-500🔒

🌐 Website

Company description

Provider of the CE-marked, globally patented ADVOS technology based on albumin dialysis—the first multi-organ support method for liver, lung, kidney, and acid-base balance. The ADVOS System enables extracorporeal elimination of CO2, hepatic toxins, water-soluble and protein-bound nephrotoxins, and correction of metabolic and respiratory acidosis. Offers ADVOS Workshops for hands-on training and ADVOS User Meetings for knowledge exchange.

Products and services

ADVOS System: CE-marked multi-therapeutic system for intensive care delivering extracorporeal albumin-dialysis-based multi-organ support, eliminating CO2, hepatic toxins, water-soluble and protein-bound nephrotoxins, and correcting metabolic and respiratory acidosis
ADVOS Workshops: Case-based training delivers practical knowledge and hands-on experience with the ADVOS system, including case discussions and error management to deepen understanding and effective use
ADVOS User Meetings: Therapy-focused networking events enabling ADVOS users to exchange knowledge and experiences and deepen understanding of ADVOS therapy through community discussions

Key contacts

🔒

Financial details

🔒

1.2 - Competitors and similar companies to Advitos

OSE Immunotherapeutics

HQ: France Website

Description: Provider of immunotherapies in immuno-oncology, auto-immune diseases, and transplantation, with a pipeline including Tedopi (Phase 3 cancer vaccine for NSCLC resistant to checkpoint inhibitors), OSE-279 (anti-PD1), BI 765063/OSE-172 (SIRPα), OSE-127 (IL-7R; ulcerative colitis), FR104 (CD28; renal transplantation), and OSE-230 (ChemR23; chronic inflammatory diseases).

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full OSE Immunotherapeutics company profile →

OrganOx

HQ: United Kingdom Website

Description: Provider of normothermic machine perfusion technology for donor livers via OrganOx metra, enabling functional assessment and preservation for up to 24 hours. Offerings support evaluation of liver function prior to transplantation, provide more flexible transplant logistics and surgery scheduling, and support complex or lengthy surgeries by extending preservation time.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full OrganOx company profile →

Paragonix Technologies

HQ: United States Website

Description: Provider of organ preservation and transport systems for heart, lung, and liver transplantation, including FDA-cleared SherpaPak Cardiac Transport System and LUNGguard, LIVERguard for static hypothermic liver preservation, and BAROguard with automated pressure regulation, plus a digital app for real-time location and temperature tracking and 24/7 clinical support for procurement and organ delivery.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Paragonix Technologies company profile →

Essential Pharma

HQ: United States Website

Description: Provider of new tools for medical researchers and manufacturers to bring performance, convenience, and control to the advancement of basic research and drug discovery, supporting the preservation and growth of human systems from the cell to the entire organ. Based in Ewing, NJ.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Essential Pharma company profile →

Oxford Immunotec

HQ: United Kingdom Website

Description: Provider of medical diagnostic tests based on patented T cell measurement technology, including T-SPOT.TB, an interferon gamma release assay for diagnosing latent TB infection and TB disease; T-SPOT.CMV for detecting cytomegalovirus infections; and T-SPOT.PRT for assessing immune responses to various pathogens.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Oxford Immunotec company profile →

🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒

🔒 View all strategic buyers with complete profiles

Start Free Trial →

2.2 - Strategic buyer groups for Advitos

🔒

Buyer group 1: ████████ ████████

●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 2: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 3: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔓 Unlock all detailed buyer group breakdowns with complete company profiles

Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Advitos

Buyout Funds
50+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US buyout funds investing in Advitos's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe buyout funds in Advitos's sector and industry vertical
View Funds →

2.2 - Growth funds investing in similar companies to Advitos

Growth Equity Funds
40+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US growth equity funds investing in Advitos's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe growth equity funds investing in Advitos's sector and industry vertical
View Funds →

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Advitos

4.2 - Public trading comparable groups for Advitos

🔒

Comparable group 1: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 2: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 3: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Advitos

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA

🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Advitos

What does Advitos do?

Advitos is a provider of the CE-marked, globally patented ADVOS technology based on albumin dialysis—the first multi-organ support method for liver, lung, kidney, and acid-base balance. The ADVOS System enables extracorporeal elimination of CO2, hepatic toxins, water-soluble and protein-bound nephrotoxins, and correction of metabolic and respiratory acidosis. Offers ADVOS Workshops for hands-on training and ADVOS User Meetings for knowledge exchange.

Who are Advitos's competitors?

Advitos's competitors and similar companies include OSE Immunotherapeutics, OrganOx, Paragonix Technologies, Essential Pharma, and Oxford Immunotec.

Where is Advitos headquartered?

Advitos is headquartered in Germany.

How many employees does Advitos have?

Advitos has 1,000 employees 🔒.

When was Advitos founded?

Advitos was founded in 2010 🔒.

What sector and industry vertical is Advitos in?

Advitos is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Advitos

Who are the top strategic acquirers in Advitos's sector and industry

Top strategic M&A buyers and acquirers in Advitos's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Advitos?

Top strategic M&A buyers groups and sectors for Advitos include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Advitos's sector and industry vertical

Which are the top PE firms investing in Advitos's sector and industry vertical?

Top PE firms investing in Advitos's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Advitos's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Advitos's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Advitos's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Advitos include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Advitos's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Advitos?

The key public trading comparables and valuation benchmarks for Advitos include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Advitos for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Advitos with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Advitos's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Advitos with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Advitos's' sector and industry vertical?

Access recent funding rounds and capital raises in Advitos's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Advitos

Start Free Trial Book a Demo